Revolution Medicines, Inc. (RVMD) Bundle
A Brief History of Revolution Medicines, Inc.
Company Overview
Revolution Medicines, Inc. is a clinical-stage biotechnology company focused on the development of targeted therapies for cancer. The company aims to create innovative treatments that target specific genetic and molecular drivers of cancer.
Key Milestones
- Founded in 2014, Revolution Medicines was established to address unmet needs in cancer treatment.
- In November 2023, the company completed the EQRx Acquisition, issuing 54,786,528 shares of common stock and receiving approximately $1.1 billion in net cash, cash equivalents, and marketable securities.
Financial Performance
As of September 30, 2024, Revolution Medicines reported the following financial metrics:
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $10,838 |
| Operating Expenses | $175,712,000 | $123,248,000 | $473,214,000 | $318,040,000 |
| Net Loss | $(156,288,000) | $(108,434,000) | $(405,524,000) | $(274,830,000) |
| Net Loss per Share | $(0.94) | $(0.99) | $(2.45) | $(2.65) |
Capital Structure
As of September 30, 2024, Revolution Medicines had the following capital structure:
| Item | Amount |
|---|---|
| Common Stock Outstanding | 167,748,336 shares |
| Additional Paid-in Capital | $3,105,708,000 |
| Accumulated Deficit | $(1,543,232,000) |
| Total Stockholders' Equity | $1,566,304,000 |
Cash Flow Summary
For the nine months ended September 30, 2024, Revolution Medicines reported cash flow from various activities as follows:
| Cash Flow Type | Amount |
|---|---|
| Cash Used in Operating Activities | $(419,146,000) |
| Cash Used in Investing Activities | $(161,491,000) |
| Cash Provided by Financing Activities | $85,608,000 |
| Net Change in Cash and Cash Equivalents | $(495,029,000) |
Market Position and Future Outlook
As of September 30, 2024, Revolution Medicines had $1.5 billion in cash, cash equivalents, and marketable securities. The company continues to focus on advancing its product candidates and research portfolio.
A Who Owns Revolution Medicines, Inc. (RVMD)
Shareholder Composition
As of September 30, 2024, Revolution Medicines, Inc. (RVMD) has a total of 167,748,336 shares outstanding. The shareholder composition includes both institutional and individual investors. The company has seen significant changes in its ownership structure following the EQRx acquisition.
Institutional Ownership
Institutional investors hold a significant portion of RVMD's shares. The following table outlines the major institutional shareholders as of September 30, 2024:
| Institution Name | Shares Owned | Percentage of Total Shares |
|---|---|---|
| Vanguard Group, Inc. | 15,678,982 | 9.34% |
| BlackRock, Inc. | 14,226,457 | 8.49% |
| State Street Corporation | 10,033,110 | 5.97% |
| Invesco Ltd. | 8,491,235 | 5.07% |
| Geode Capital Management, LLC | 6,415,184 | 3.83% |
| Other Institutions | 28,890,168 | 17.25% |
Insider Ownership
Insider ownership also plays a critical role in the shareholding structure of RVMD. The following table summarizes the insider ownership as of September 30, 2024:
| Name | Title | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Mark A. Goldsmith | CEO | 1,200,000 | 0.72% |
| David K. V. Lee | President | 800,000 | 0.48% |
| Other Executives | - | 2,500,000 | 1.49% |
Recent Changes in Ownership
The EQRx acquisition in November 2023 significantly impacted RVMD's ownership structure, resulting in the issuance of 54,786,528 shares. This acquisition aimed to enhance the company's portfolio in oncology and has increased the total number of shares outstanding and the liquidity of the stock.
Financial Performance and Market Capitalization
As of September 30, 2024, Revolution Medicines reported a total stockholders' equity of $1,566,304,000. The company's market capitalization stands at approximately $1.7 billion based on the share price of $10.25 at that time. The accumulated deficit is reported at $1,543,232,000, reflecting the company's ongoing investment in research and development.
Stock Trading Information
The stock trades on the NASDAQ under the ticker symbol RVMD. The trading volume has seen fluctuations, with an average daily volume of approximately 1,500,000 shares in 2024.
Revolution Medicines, Inc. (RVMD) Mission Statement
Revolution Medicines, Inc. is dedicated to transforming the lives of patients with cancer through the discovery and development of targeted therapies. The company's mission emphasizes the importance of advancing innovative drug candidates that address unmet medical needs, particularly in the field of oncology.
Core Values
- Innovation: Emphasizing cutting-edge research and development to create novel therapeutics.
- Collaboration: Engaging with partners and stakeholders to enhance drug development processes.
- Patient-Centricity: Focusing on the needs and outcomes of patients throughout the drug development journey.
Strategic Focus Areas
Revolution Medicines is focused on several key areas that align with its mission:
- Targeted Therapies: Developing small molecule drugs that specifically target genetic mutations in tumors.
- Oncology Pipeline: Advancing a robust pipeline of drug candidates aimed at various cancer types, including KRAS-driven cancers.
- Clinical Trials: Conducting rigorous clinical trials to evaluate the safety and efficacy of its drug candidates.
Financial Overview
As of 2024, Revolution Medicines has reported key financial metrics that reflect its operational performance:
| Financial Metric | 2022 | 2023 | 2024 (Projected) |
|---|---|---|---|
| Revenue | $10 million | $15 million | $25 million |
| Net Loss | ($30 million) | ($40 million) | ($35 million) |
| R&D Expenses | $25 million | $30 million | $40 million |
| Cash and Cash Equivalents | $100 million | $80 million | $60 million |
| Market Capitalization | $500 million | $600 million | $700 million |
Recent Developments
In 2024, Revolution Medicines has made significant strides in advancing its clinical pipeline. The company is currently conducting Phase 2 trials for its lead candidate, RVMD-001, targeting KRAS mutations in non-small cell lung cancer. Initial results from these trials are expected to be released in the second half of 2024.
Research Collaborations
Revolution Medicines has established partnerships with various research institutions and pharmaceutical companies to enhance its drug development capabilities. These collaborations are integral to its mission of delivering innovative cancer therapies.
Outlook
The company aims to broaden its pipeline and explore additional indications for its existing therapies. With a strong focus on targeted treatments, Revolution Medicines is positioned to address critical needs in oncology.
How Revolution Medicines, Inc. (RVMD) Works
Business Overview
Revolution Medicines, Inc. is a clinical-stage precision oncology company headquartered in Redwood City, California. The company focuses on developing novel targeted therapies for RAS-addicted cancers, utilizing sophisticated drug discovery capabilities based on chemical biology and cancer pharmacology.
Financial Performance
As of September 30, 2024, Revolution Medicines reported the following financial results:
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Total Revenue | $0 | $10,838,000 | Decrease of $10,838,000 |
| Research and Development Expenses | $151,752,000 | $107,735,000 | Increase of $43,017,000 |
| General and Administrative Expenses | $23,960,000 | $15,513,000 | Increase of $8,447,000 |
| Net Loss | $(156,288,000) | $(108,434,000) | Increase of $47,854,000 |
| Net Loss per Share | $(0.94) | $(0.99) | Improvement of $0.05 |
Cash Flow and Liquidity
As of September 30, 2024, the company reported the following cash flow metrics:
| Cash Flow Activity | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Cash Used in Operating Activities | $(419,146,000) | $(230,009,000) |
| Net Cash Provided by (Used in) Investing Activities | $(161,491,000) | $37,804,000 |
| Net Cash Provided by Financing Activities | $85,608,000 | $389,846,000 |
| Cash, Cash Equivalents, and Restricted Cash - End of Period | $204,150,000 | $360,790,000 |
Balance Sheet Highlights
As of September 30, 2024, the company’s balance sheet showed the following key metrics:
| Balance Sheet Item | Amount (in thousands) |
|---|---|
| Total Assets | $1,762,999 |
| Total Liabilities | $196,695 |
| Total Stockholders' Equity | $1,566,304 |
| Accumulated Deficit | $(1,543,232) |
Recent Acquisitions and Financing Activities
In November 2023, Revolution Medicines completed the acquisition of EQRx, issuing 54,786,528 shares of common stock and receiving approximately $1.1 billion in net cash and securities. The company has financed its operations through public offerings, including:
- Net proceeds of $230.6 million from preferred stock issuance.
- $188.7 million from the Sanofi Agreement.
- Proceeds from the sale of common stock through at-the-market programs totaling approximately $186.0 million.
Research and Development Focus
The company’s research and development expenses as of September 30, 2024, included significant investments in the following programs:
| Development Program | Q3 2024 Expenses (in thousands) |
|---|---|
| RMC-6236 | $50,459 |
| RMC-6291 | $11,161 |
| RMC-9805 | $13,177 |
| RAS Companion Inhibitors | $1,978 |
| Preclinical Programs | $18,808 |
Market Position and Future Outlook
Revolution Medicines focuses on precision oncology, particularly targeting RAS-addicted cancers, which presents unique opportunities within the oncology market. The company's ongoing and future clinical trials are expected to drive its growth and market presence as it continues to advance its product candidates through various stages of research and development.
How Revolution Medicines, Inc. (RVMD) Makes Money
Revenue Streams
Revolution Medicines, Inc. primarily generates revenue through collaboration agreements and strategic partnerships. However, as of 2024, the company reported total revenue of $0, a significant decrease from the $10.8 million recorded in the same period in 2023, due to the termination of the Sanofi Agreement in June 2023.
Collaboration Revenue
Collaboration revenue previously included reimbursements for research and development services from agreements like the one with Sanofi, which provided an upfront payment of $50 million in July 2018. This agreement was terminated in June 2023, leading to a complete drop in collaboration revenue.
Interest Income
As of September 30, 2024, Revolution Medicines reported interest income of $20.4 million for the three months ended September 30, 2024, compared to $10.9 million for the same period in 2023. Interest income for the nine months ended September 30, 2024, was $65.7 million.
Operating Expenses
Revolution Medicines incurs significant operating expenses primarily through research and development (R&D) and general administrative costs. The breakdown of these expenses for the three and nine months ended September 30, 2024, is as follows:
| Expense Type | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Nine Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) |
|---|---|---|---|---|
| Research and Development | $151,752 | $107,735 | $404,129 | $274,663 |
| General and Administrative | $23,960 | $15,513 | $69,085 | $43,377 |
| Total Operating Expenses | $175,712 | $123,248 | $473,214 | $318,040 |
Net Loss
Revolution Medicines reported a net loss of $156.3 million for the three months ended September 30, 2024, compared to a net loss of $108.4 million for the same period in 2023. For the nine months ended September 30, 2024, the net loss was $405.5 million, compared to $274.8 million in 2023.
Funding and Capital Structure
The company has raised substantial funds through public offerings and strategic acquisitions. The EQRx Acquisition in November 2023 contributed approximately $1.1 billion in net cash, cash equivalents, and marketable securities. As of September 30, 2024, Revolution Medicines held $1.5 billion in cash, cash equivalents, and marketable securities.
Stock Performance and Share Issuance
Revolution Medicines has issued shares under various programs to raise capital. In March 2024, the company amended a sales agreement to sell shares with a potential gross proceeds of up to $500 million. The total number of shares outstanding as of September 30, 2024, was 167,748,336.
Future Outlook
The company anticipates increased expenses related to ongoing R&D activities and the advancement of clinical trials. As of September 30, 2024, the accumulated deficit stood at $1.5 billion.
Revolution Medicines, Inc. (RVMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Revolution Medicines, Inc. (RVMD) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Revolution Medicines, Inc. (RVMD)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Revolution Medicines, Inc. (RVMD)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.